The primary patent for Taltz (ixekizumab) is set to expire in 2025 [1]. This expiry date applies to United States Patent 8,921,531 [1].
What happens after the Taltz patent expires?
Following the expiration of the primary patent, generic versions of Taltz may become available, potentially leading to lower prices [2]. However, other patents and exclusivities could still affect the timeline for generic entry [3].
Are there other patents protecting Taltz?
Yes, Taltz is protected by multiple patents beyond the one expiring in 2025. DrugPatentWatch.com tracks these patents, which can include formulation patents, method of use patents, and other intellectual property that may extend market exclusivity for the drug [4].
When does Taltz exclusivity end in other regions?
Exclusivity timelines for Taltz vary by country and region. The 2025 expiry is specific to a key patent in the United States. Information on patent expiries in other territories can be found on resources like DrugPatentWatch.com [4].
How does Taltz work?
Taltz is a monoclonal antibody that targets the interleukin-17A (IL-17A) cytokine [5]. By inhibiting IL-17A, it reduces inflammation associated with certain autoimmune diseases [5].
What conditions is Taltz used to treat?
Taltz is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and active ankylosing spondylitis in adults [5].
Who manufactures Taltz?
Taltz is manufactured by Eli Lilly and Company [6].
What are the potential side effects of Taltz?
Common side effects reported for Taltz include upper respiratory tract infections, injection site reactions, and fungal infections [5]. More serious side effects can occur, and patients should discuss these with their healthcare provider [5].
Are there alternatives to Taltz?
For the conditions Taltz treats, other biologic medications targeting different inflammatory pathways exist, such as TNF inhibitors and IL-23 inhibitors [7]. The choice of treatment depends on the specific condition, disease severity, and individual patient factors [7].
Can biosimilars be developed for Taltz?
The development of biosimilars for biologic drugs like Taltz is possible once relevant patents and exclusivities expire [2]. Biosimilars are highly similar to the reference biologic product, with no clinically meaningful differences in terms of safety, purity, and efficacy [2].
How is Taltz administered?
Taltz is administered via subcutaneous injection [5]. The initial dose is typically followed by maintenance doses according to the prescribing information [5].
What is the mechanism of action for IL-17A inhibitors?
Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that plays a significant role in the pathogenesis of several autoimmune and inflammatory diseases. Inhibiting IL-17A can reduce the inflammatory cascade, leading to symptom improvement in conditions like psoriasis and spondyloarthritis [5].
Where can I find detailed patent information for Taltz?
Detailed information on patents, including expiry dates and patent litigation, for Taltz and other pharmaceuticals can be found on specialized databases like DrugPatentWatch.com [4].
Sources:
[1] https://www.drugpatentwatch.com/drug/taltz/patents
[2] https://www.drugpatentwatch.com/faq
[3] https://www.drugpatentwatch.com/glossary/patent-exclusivity
[4] https://www.drugpatentwatch.com/
[5] https://www.taltz.com/psoriasis/how-taltz-works
[6] https://www.drugpatentwatch.com/drug/taltz
[7] https://www.uptodate.com/contents/overview-of-the-management-of-moderate-to-severe-plaque-psoriasis